In a current opinion piece in Newsweek, Dr. Rahul Tiwari asserts that pharmaceutical firms in India have a chance to supplant China’s dominant place in producing lively pharmaceutical substances (“API’s”) and different uncooked supplies which are crucial parts within the U.S. drug provide chain. There have clearly been rising tensions between the U.S. and China, and shortages throughout the starting of the COVID epidemic delivered to the forefront how dependent the U.S. pharmaceutical provide chain is on China. Although that has led to elevated calls by U.S. policymakers to onshore the manufacturing of API’s and different substances, Tiwari notes that value is a significant obstacle to wholesale manufacturing throughout the U.S., particularly for generic medicine.

Tiwari means that India’s good relationship with and shut financial ties to the U.S. could be leveraged to allow pharmaceutical firms in India to take China’s place within the U.S. provide chain and assuage the considerations of U.S. policymakers. But Tiwari additionally acknowledges that doing so would require vital funding and technological enhancements. In addition, Indian firms must be significantly centered on navigating U.S. patent points and FDA’s complicated regulatory regime.

India actually appears poised to extend its function within the U.S. pharmaceutical provide chain. It will probably be fascinating to see if Tiwari’s prediction of India overtaking China’s function will come to fruition.

“By collaborating with India, the United States can scale back its dependency on China, fostering a safer and diversified provide chain.

www.newsweek.com/…